A phase I dose-escalation study of the MDM2-p53 antagonist BI 907828 in patients (pts) with advanced solid tumors.

被引：9
|
作者：
LoRusso, Patricia
Gounder, Mrinal M.
Patel, Manish R.
Yamamoto, Noboru
Bauer, Todd Michael
Laurie, Scott
Grempler, Rolf
Davenport, Teffany
Geng, Junxian
Rohrbacher, Maren
Lahmar, Mehdi
机构：
[1] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Florida Canc Specialists & Res Inst, Sarah Cannon Res Inst, Sarasota, FL USA
[4] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
[5] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[6] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada
[7] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[8] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[9] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.3016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3016
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase I, dose-escalation, safety, pharmacokinetic, pharmacodynamic study of thioureidobutyronitrile, a novel p53 targeted therapy, in patients with advanced solid tumors.
    Shapiro, Geoffrey
    Supko, Jeffrey G.
    Cho, Daniel C.
    Hilton, John Frederick
    Hadfield, Matthew
    Pruitt-Thompson, Salida
    Bordoli-Trachsela, Eveline
    Zvereva, Nela
    Wolanski, Andrew
    Sato-DiLorenzo, Aya
    Gotthardt, Susan
    Fox, Edward A.
    Verselis, Sigitas Jonas
    Kumar, Ashok
    Holden, Sylvia A.
    Ram, Siya
    Chafai-Fadela, Karima
    Harding, Kimberly
    Menon, Krishna E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Brightline-1: phase II/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS
    Schoffski, Patrick
    Lahmar, Mehdi
    Lucarelli, Anthony
    Maki, Robert G.
    FUTURE ONCOLOGY, 2022, 19 (09) : 621 - 629
  • [23] Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series
    Yamamoto, Noboru
    Tolcher, Anthony
    Hafez, Navid
    Lugowska, Iwona
    Ramlau, Rodryg
    Macarulla, Teresa
    Geng, Junxian
    Li, Jian
    Teufel, Michael
    Maerten, Angela
    LoRusso, Patricia
    ONCOTARGETS AND THERAPY, 2024, 17 : 267 - 280
  • [24] Phase I, dose-escalation study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    LoRusso, Patricia
    Ribas, Antoni
    Sosman, Jeffrey Alan
    Pavlick, Anna C.
    Dy, Grace K.
    Zhou, Xiaofei
    Gangolli, Esha A.
    Walker, Russell M.
    Kneissl, Michelle
    Faucette, Stephanie
    Neuwirth, Rachel
    Bozon, Viviana
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [25] A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumors.
    Berlin, Jordan
    Ramanathan, Ramesh K.
    Strickler, John H.
    Subramaniam, Deeps Suresh
    Hurwitz, Herbert
    Kang, Yoon-Koo
    Kim, Tae-You
    Shepherd, Stacie Peacock
    Xiong, Hao
    Hetman, Robert
    Nickner, Caroline
    Dudley, Matthew W.
    Giranda, Vincent L.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Phase I Dose-Escalation Study of Ramucirumab in Chinese Patients with Advanced Solid Tumors
    Cao, Junning
    Ji, Dongmei
    Chen, Zhiyu
    Shen, Weina
    Wang, Jin
    Li, Baoyue
    Chi, Haidong
    Long, Amanda
    Gao, Ling
    Li, Jin
    ONCOLOGIST, 2017, 22 (06): : 638 - +
  • [27] Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors
    Demetri, George D.
    Lo Russo, Patricia
    MacPherson, Lain R. J.
    Wang, Ding
    Morgan, Jeffrey A.
    Brunton, Valerie G.
    Paliwal, Prashni
    Agrawal, Shruti
    Voi, Maurizio
    Evan, T. R. Jeffry
    CLINICAL CANCER RESEARCH, 2009, 15 (19) : 6232 - 6240
  • [28] A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors.
    Adjei, A. A.
    Sosman, J. A.
    Dy, G. K.
    Ma, W.
    Fetterly, G. J.
    Skupien, D.
    Means, J. A.
    Savage, R.
    Chai, F.
    Puzanov, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors.
    Ho, A. L.
    Bendell, J. C.
    Cleary, J. M.
    Schwartz, G. K.
    Burris, H. A.
    Oakes, P.
    Agbo, F.
    Barker, P. N.
    Senderowicz, A. M.
    Shapiro, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [30] A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors
    Ahnert, J. Rodon
    Baselga, J.
    Tawbi, H. A.
    Shou, Y.
    Granvil, C.
    Dey, J.
    Mita, M. M.
    Thomas, A. L.
    Amakye, D. D.
    Mita, A. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345